#United States #Huntsville #Ampersand Capital #Gannet BioChem #Nektar Therapeutics

Ampersand Capital Partners Acquires Nektar’s PEG Reagent Manufacturing Business

In a significant development in the biopharmaceutical sector, Ampersand Capital Partners has successfully completed the acquisition of Nektar Therapeutics' polyethylene glycol (PEG) reagent manufacturing business. This acquisition has led to the launch of a new subsidiary, Gannet BioChem, which will continue to operate from its state-of-the-art facility located in Huntsville, Alabama.

The establishment of Gannet BioChem marks a strategic entry into the world of Contract Development and Manufacturing Organizations (CDMOs) focused on PEG reagents, which are critical for advanced therapeutic products. Gannet BioChem comes with over 30 years of experience in developing and manufacturing PEG reagents, a critical component in biopharmaceutical applications.

Why PEG Reagents Matter

PEGylation is a process that involves attaching polyethylene glycol molecules to drugs, enhancing their therapeutic properties and bioavailability. This is particularly crucial in developing biologic therapies targeting complex diseases. Gannet BioChem has a robust reputation in this domain, already supplying PEG reagents for numerous FDA-approved therapeutics throughout its operational history.

Features of Gannet BioChem

Gannet BioChem is not just another entry in the biopharmaceutical landscape; it combines advanced technology with a dedicated workforce, ensuring high-quality output. Here are some of the features that set Gannet BioChem apart:

• - End-to-End GMP Production: Gannet BioChem offers comprehensive production capabilities—from sourcing raw materials to final packaging—guaranteeing quality at every supply chain stage.
• - FDA-Approved Applications: The facility has developed and produced PEG reagents utilized in nine FDA-approved therapeutic applications, reflecting a commitment to meeting regulatory standards and quality benchmarks.
• - Flexible Facility: Capable of managing production from small scales to mass commercial output, Gannet BioChem's facility is designed for operational flexibility.
• - Expert Team: The workforce enjoys an average tenure of 13 years, bringing experience and continuity in producing specialized PEG reagents.
• - Expansion-Ready Infrastructure: Covering 124,000 square feet, the facility is equipped not just for current production needs but is also poised for future growth to support expanding customer requirements.
• - Strategic Location: Its positioning near the second-largest life sciences research park in the USA facilitates partnerships and innovation in biotechnology.
• - Legacy of Quality: Gannet BioChem maintains an enviable compliance record under FDA inspections, emphasizing its dedication to quality assurance and reliability.

Vision and Future Plans

David Anderson, General Partner at Ampersand Capital Partners, expressed his enthusiasm regarding the new venture. He believes the seasoned PEG reagent team at Gannet BioChem is well-positioned to leverage Ampersand's resources and expertise in life sciences, enhancing the company’s growth trajectory. Anderson stated, “We are thrilled to introduce Gannet BioChem as a new, independent PEG reagents CDMO with a legacy of high-quality delivery in specialty reagents for both commercial and clinical-stage biologics.”

The acquisition is set to not only expand Ampersand's portfolio but also to foster collaborations in the biotechnology sector, catering to innovative companies looking to refine their therapeutic development capabilities.

About Ampersand Capital Partners

Established in 1988, Ampersand Capital Partners is a private equity firm specializing in growth investments in the healthcare sector. With assets under management amounting to $3 billion, the firm has been instrumental in developing several market-leading companies, particularly in life sciences.

For more details, visit their websites, AmpersandCapital.com and GannetBioChem.com, or connect with them on LinkedIn to keep abreast of advancements in their portfolio and initiatives.

Conclusion

As the biopharmaceutical industry continues to evolve, the establishment of Gannet BioChem represents a strategic move by Ampersand Capital Partners, heralding potential advancements in the development of innovative treatments. This acquisition symbolizes a commitment to fostering innovation in life sciences, ultimately benefitting patients worldwide.